Economia

COMUNICATO STAMPA - Responsabilità editoriale di Business Wire

BiologyWorks k(now)™ COVID-19 Clinical Trial Matches 99.1% Accuracy to RT-PCR Tests

BiologyWorks k(now)™ Handheld Molecular Testing Device Among the Most Accurate for COVID-19

Business Wire

BiologyWorks™, Inc., a digital healthcare platform company, today announced that a substantive clinical trial of its handheld, reusable molecular test for COVID-19 matched 99.1% accuracy to laboratory RT-PCR tests.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220116005038/en/

k(now) handheld molecular testing device (Photo: Business Wire)

k(now) handheld molecular testing device (Photo: Business Wire)

The independent clinical trial, conducted by Locus Medicus in Athens, Greece, prospectively tested 330 patients with symptomatic and asymptomatic cases of COVID-19. For the study, staff at the clinical laboratory collected two bilateral anterior nasal swabs from each patient. Immediately after collection, one swab was tested in the lab’s standard of care CE-Mark RT-PCR test and the other swab was tested by BiologyWorks k(now). Results from the BiologyWorks k(now) molecular test were 99.1% in overall percent agreement with the results of the RT-PCR lab tests.

In addition to the clinical trial conducted by Locus Medicus, other independent validation studies of BiologyWorks k(now) have been conducted by the University of California, Los Angeles (UCLA), the Los Angeles County Department of Health Services and Streeklab in Haarlem, Netherlands. Moreover, the Company verified the efficacy of BiologyWorks k(now) with over 12,000 tests in its Southern California lab. These studies also validate that the BiologyWorks k(now) molecular COVID-19 test provides RT-PCR lab quality results.

“Our Company’s priority is to make lab-quality testing accessible, accurate and affordable for everyone,” said Hunt Ramsbottom, CEO of BiologyWorks. “These clinical trials confirm that our handheld, reusable test is among the most accurate for COVID-19.” Hunt continued, “We give individuals and providers a highly reliable testing platform, with significantly lower cost per result and shortened time to results.”

BiologyWorks’ molecular test works in conjunction with the k(now) PRO™ digital platform, which provides point-of-care (POC) providers with a complete solution for end-to-end testing management. POC providers and patients simultaneously receive verified results within 45 minutes, giving individuals control of their health data. The BiologyWorks k(now) PRO digital platform complies with the most rigorous privacy standards, including the Health Insurance Portability and Accountability Act (HIPAA) and the EU General Data Protection Regulation (GDPR).

About BiologyWorks

BiologyWorks™ (www.biologyworks.com) is the creator of BiologyWorks k(now)™ molecular test and the k(now) PRO™ digital platform. Together, these products offer point-of-care providers with a complete solution for highly accurate and affordable end-to-end testing management. The Company’s chemistry is patent-protected, based on research originating with the Alfred Mann Foundation, and is underwritten by a grant from the Bill & Melinda Gates Foundation.

For sales inquiries, please contact: sales@biologyworks.com

Nancy Perlman
nancy@biologyworks.com

Permalink: http://www.businesswire.com/news/home/20220116005038/en

COMUNICATO STAMPA - Responsabilità editoriale di Business Wire

Video Economia



Vai al sito: Who's Who

Modifica consenso Cookie